JWH073

JWH-073 is a synthetic cannabinoid in the naphthoylindole class, part of the JWH series developed by researchers led by John W. Huffman at Clemson University to study cannabinoid receptors. Like other naphthoylindoles, it consists of a naphthoyl group attached to an indole core, typically with an alkyl substituent on the indole nitrogen. This structural class is known for producing potent cannabinoid receptor activity compared with natural cannabis compounds.

Pharmacologically, JWH-073 acts as an agonist at cannabinoid receptors, primarily CB1 and CB2, and has demonstrated significant cannabimimetic effects in preclinical investigations. In several assays, JWH-073 has shown high receptor affinity and potency relative to delta-9-tetrahydrocannabinol (THC), contributing to pronounced psychoactive and physiologic effects at comparatively low doses.

Historically, JWH-073 surfaced in the designer-drug market during the late 2000s and early 2010s, where it was used as a cannabis substitute in various illicit products. Its appearance prompted regulatory responses in multiple jurisdictions, with many countries scheduling or restricting JWH compounds or related naphthoylindoles to curb abuse and associated health risks.

Safety and regulation: Use of JWH-073 has been linked to adverse effects such as tachycardia, hypertension, agitation, anxiety, confusion, and, in some cases, more severe neurologic or psychiatric symptoms. The variability and unknown purity of illicit preparations contribute to heightened risk. Regulatory status varies by country, but it has commonly been controlled or banned as a synthetic cannabinoid.

See also: other JWH cannabinoids and synthetic cannabinoids.